DB±ÝÀ¶ÅõÀÚ¿¡¼­ 27ÀÏ SK¹ÙÀÌ¿ÀÆÊ(326030)¿¡ ´ëÇØ "Efficacy¿¡ TolerabilityÀÇ ½Ã³ÊÁö"¶ó¸ç ÅõÀÚÀÇ°ßÀ» 'BUY'·Î Á¦½ÃÇÏ¿´°í, ¾Æ¿ï·¯ ¸ñÇ¥ÁÖ°¡·Î´Â 140,000¿øÀ» ³»³õ¾Ò´Ù.

DB±ÝÀ¶ÅõÀÚ ÀÌ¸í¼± ¾Ö³Î¸®½ºÆ®°¡ µ¿Á¾¸ñ¿¡ ´ëÇÏ¿© À̹ø¿¡ Á¦½ÃÇÑ 'BUY'ÀÇ°ßÀº DB±ÝÀ¶ÅõÀÚÀÇ Á÷Àü ¸Å¸ÅÀÇ°ß¿¡¼­ Å« º¯È­¾øÀÌ ±×´ë·Î À¯ÁöµÇ´Â °ÍÀÌ°í ¿ÃÇØ ÃʹÝÀÇ ¸Å¸ÅÀÇ°ßÀ» ±âÁØÀ¸·Î º¼¶§µµ ¿ª½Ã '¸Å¼ö'ÀÇ°ßÀÌ °è¼Ó À¯ÁöµÇ°í ÀÖ´Â »óÅÂÀÌ´Ù. ±×¸®°í ÃÖ±Ù ºÐ±â³» ¹ßÇ¥µÈ Àüü Áõ±Ç»ç ¸®Æ÷Æ®ÀÇ ÄÁ¼¾¼­½º¿Í ºñ±³¸¦ Çغ¼ °æ¿ì¿¡ ¿À´Ã ¹ßÇ¥µÈ ÅõÀÚÀÇ°ßÀº ÀüüÀÇ°ß¿¡ ¼ö·ÅÇÏ°í ÀÖ¾î, À̹ø ÀÇ°ßÀº ½ÃÀåÀÇ Æò±ÕÀûÀÎ ±â´ë°¨ÀÌ °´°üÀûÀ¸·Î Ç¥ÇöµÈ °ÍÀ¸·Î ºÐ¼®µÇ°í ÀÖ´Ù.

¸ñÇ¥ÁÖ°¡ÀÇ ÃßÀ̸¦ »ìÆ캸¸é ÃÖ±Ù Àå±â°£ ¸ñÇ¥°¡°¡ °°Àº ¼öÁØ¿¡ ¸Ó¹°°í ÀÖ´Â ¸ð½ÀÀÌ´Ù.

¡ß Report statistics

DB±ÝÀ¶ÅõÀÚÀÇ µ¿Á¾¸ñ¿¡ ´ëÇÑ ÃÖ±Ù 6°³¿ù µ¿¾ÈÀÇ ÅõÀÚÀÇ°ßÀº ÀüüÀûÀ¸·Î Å« º¯È­¾øÀÌ À¯ÁöµÇ°í ÀÖ´Ù.

¿À´Ã DB±ÝÀ¶ÅõÀÚ¿¡¼­ ¹ßÇ¥µÈ 'BUY'ÀÇ°ß ¹× ¸ñÇ¥ÁÖ°¡ 140,000¿øÀº ÀüüÀÇ°ß¿¡ ¼ö·ÅÇϸ鼭 ½ÃÀåÀÇ Æò±ÕÀûÀÎ ±â´ë°¨ÀÌ ºñ±³Àû °´°üÀûÀ¸·Î Ç¥ÇöµÈ °ÍÀ¸·Î Ç®ÀÌµÇ¸ç ¸ñÇ¥°¡Æò±Õ ´ëºñ 4%Á¤µµ ¹Ì´ÞÇÏ°í ÀÖ´Â °ÍÀ¸·Î Áý°èµÇ¾ú´Ù. Âü°í·Î ÃÖ±Ù¿¡ ¸ñÇ¥ÁÖ°¡¸¦ °¡Àå °ø°ÝÀûÀ¸·Î Á¦½ÃÇÑ Çѱ¹ÅõÀÚÁõ±ÇÀº ÅõÀÚÀÇ°ß '¸Å¼ö'¿¡ ¸ñÇ¥ÁÖ°¡ 160,000¿øÀ» Á¦ÀÏ º¸¼öÀûÀÎ ÀÇ°ßÀ» Á¦½ÃÇÑ Å°¿òÁõ±ÇÀº ÅõÀÚÀÇ°ß 'BUY'¿¡ ¸ñÇ¥ÁÖ°¡ 120,000¿øÀ» Á¦½ÃÇÑ ¹Ù ÀÖ´Ù.

[DB±ÝÀ¶ÅõÀÚ ÅõÀÚÀÇ°ß ÃßÀÌ]

- 2026.08.27 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY

- 2026.05.08 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY

- 2026.02.09 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY

- 2025.11.12 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY

- 2025.11.06 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY

[Àüü Áõ±Ç»ç ÃÖ±Ù ¸®Æ÷Æ®]

- 2026.08.27 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY DB±ÝÀ¶ÅõÀÚ

- 2026.08.27 ¸ñÇ¥°¡ 140,000 ÅõÀÚÀÇ°ß BUY »ï¼ºÁõ±Ç

- 2026.08.27 ¸ñÇ¥°¡ 160,000 ÅõÀÚÀÇ°ß BUY ¸Þ¸®Ã÷Áõ±Ç

- 2026.08.27 ¸ñÇ¥°¡ 155,000 ÅõÀÚÀÇ°ß BUY DSÅõÀÚÁõ±Ç